A detailed history of Claret Asset Management Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Claret Asset Management Corp holds 4,326 shares of HALO stock, worth $302,949. This represents 0.04% of its overall portfolio holdings.

Number of Shares
4,326
Holding current value
$302,949
% of portfolio
0.04%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$52.92 - $78.28 $228,931 - $338,639
4,326 New
4,326 $317,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Claret Asset Management Corp Portfolio

Follow Claret Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Claret Asset Management Corp with notifications on news.